China Sets Clinical Trial Record But Starting Studies Can Be Challenging

Innovation Drive Meets Economic Downturn

Antibody-drug conjugates, GLP-1 receptor agonists and cell/gene therapies propelled a big increase in clinical trial registrations in China last year, but why do sponsors sometimes remain reluctant to actually start studies?

China flag with arrow graph going up showing strong economy and shares rise. Profit and success. Isolated vector illustration.
China reports record-breaking clinical trial registrations, but time to study start remains lengthy • Source: Shutterstock

China has broken its own record for the number of clinical trial registrations in one year, with the total surging by 26% in 2023 to reach 4,300, notes a new annual report from the country's Center for Drug Evaluation.

The tally, released on 20 May, is not only a major step up from 3,410 the previous year, but also...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from China

More from Asia